Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

15.7 -2.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16

Max

16.44

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+95.06% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-71M

1.3B

Ankstesnė atidarymo kaina

18.61

Ankstesnė uždarymo kaina

15.7

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-09 23:56; UTC

Event

United Airlines shares are higher in after-market trading ahead of its Q2 FY2026 earnings announcement, with EPS expected at $1.81 and revenue at $17.6 billion.

2026-07-09 23:56; UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

2026-07-09 23:56; UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

2026-07-09 23:56; UTC

ETF Constituents
Macro News
Correlated Moves

The VanEck Gold Miners ETF rose in after-market hours amid positive sentiment for gold mining assets and a drop in crude oil prices.

2026-07-09 23:52; UTC

Correlated Moves

The iShares TIPS Bond ETF is trading lower in after-market hours, reflecting broader market sentiment and remaining below its 20-day moving average.

2026-07-09 23:51; UTC

Ross Stores Inc. shares are lower in after-market hours, declining since Thursday's close and remaining below the 20-day moving average.

2026-07-09 23:51; UTC

Fox Corp shares are higher in after-market hours, despite remaining below their 20-day moving average amid broader market fluctuations and declining jobless claims.

2026-07-09 23:51; UTC

U.S. equity markets remain flat amid geopolitical tensions and mixed economic signals, while Treasury yields decline and tech stocks show resilience.

2026-07-09 23:51; UTC

Global equity markets rise, led by Asia, while U.S. indices remain flat amid mixed economic data and geopolitical tensions; jobless claims drop unexpectedly but home sales decline raises housing market concerns.

2026-07-09 23:51; UTC

European equity markets rise on strong German export data and easing geopolitical tensions, while bond yields increase amid inflation concerns.

2026-07-09 23:51; UTC

Asia equity markets rise amid geopolitical tensions, while China's vehicle sales decline and Japan's machine tool orders soar, as U.S. jobless claims drop unexpectedly.

2026-07-09 23:51; UTC

Brazil's Retail Sales Report on July 16 Expected to Show Recovery After April Decline, Boosting Economic Sentiment Amid Global Uncertainties.

2026-07-09 23:51; UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

2026-07-09 23:51; UTC

Correlated Moves
ETF Constituents
Macro News

Vanguard Real Estate ETF gained after-market hours, supported by easing crude oil prices and positive sentiment from potential diplomatic resolutions between Iran and the U.S.

2026-07-09 23:51; UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

2026-07-09 23:51; UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

2026-07-09 23:46; UTC

Sirius XM Holdings Inc shares are lower in after-market trading. No specific news was identified to explain the price movement.

2026-07-09 23:46; UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

2026-07-09 23:46; UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

2026-07-09 23:42; UTC

Upcoming U.S. CPI Release on July 14, 2026, Expected to Reflect Rising Inflation Pressures Amidst Food Price Concerns and Geopolitical Tensions Impacting Energy Costs.

2026-07-09 23:42; UTC

Core Inflation Rate YoY for June 2026 set to release on July 14, with a forecast of 2.9%, amid rising inflation concerns and cautious market sentiment regarding potential interest rate hikes.

2026-07-09 23:42; UTC

Core Inflation Rate MoM for June 2026 set to rise by 0.3% amid geopolitical tensions and surging oil prices, impacting investor sentiment ahead of the report release on July 14.

2026-07-09 23:42; UTC

CPI Release on July 14, 2026 Sparks Caution Among Investors Amid Rising Inflation and Geopolitical Tensions.

2026-07-09 23:42; UTC

U.S. Inflation Rate Expected to Rise Amidst Economic Pressures and Consumer Behavior Shifts, Set for Release on July 14, 2026

2026-07-09 23:42; UTC

U.S. June Inflation Rate Release on July 14 Expected to Show Slight Decrease Amid Geopolitical Tensions and Economic Uncertainty

2026-07-09 23:41; UTC

ETF Constituents

After-market trading for iShares MSCI South Korea ETF is near unchanged, with SK Telecom Co. contributing a return of 0.67%. Global equity indices are generally higher.

2026-07-09 23:41; UTC

Macro News
Correlated Moves

Bitcoin rises to $63,300 amid improved sentiment from U.S.-Iran negotiations and falling crude oil prices, boosting risk assets including cryptocurrencies.

2026-07-09 23:36; UTC

Correlated Moves

The US 30Y Treasury Bond Index is higher during Thursday's session, reflecting a general upward movement since the previous close.

2026-07-09 23:36; UTC

Ulta Beauty Inc. shares advanced in after-market trading, despite no specific news. Market sentiment remains influenced by geopolitical tensions affecting oil prices.

2026-07-09 23:36; UTC

ETF Constituents

After-market trading for the Communication Services Select Sector SPDR Fund remains roughly flat, with slight declines from Netflix and Alphabet Inc. contributing to performance.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

95.06% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  95.06%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat